Since pharmacological EZH2 inhibitors have been used in the treatment of tumors in either preclinical studies or clinical trials [38, 39], our findings suggest the a potential use of EZH2 inhibitors as a treatment for ARDS-associated fibrosis. The gene discussed is EZH2; the disease is acute respiratory distress syndrome.